Vertex Pharmaceuticals (VRTX) Long-Term Investments (2016 - 2026)

Vertex Pharmaceuticals' Long-Term Investments history runs 7 years deep, the most recent figure standing at $5.7 billion for Q1 2026.

• On a quarterly basis, Long-Term Investments rose 11.51% year-over-year to $5.7 billion in Q1 2026; TTM through Mar 2026 was $5.7 billion, a 11.51% increase from a year earlier, with the FY2025 full-year figure at $5.7 billion, up 11.83% from the prior year.
• Long-Term Investments climbed to $5.7 billion in Q1 2026 per VRTX's latest filing, from $5.7 billion in the prior quarter.
• Across five years, Long-Term Investments topped out at $5.7 billion in Q1 2026 and bottomed at $112.2 million in Q4 2022.
• The 5-year median for Long-Term Investments is $4.5 billion (2024), against an average of $3.8 billion.
• Across the five-year window, Long-Term Investments soared 2126.2% in 2023 and increased 11.51% in 2026, its largest moves.
• Year by year, Long-Term Investments stood at $112.2 million in 2022, then surged by 2126.2% to $2.5 billion in 2023, then soared by 104.5% to $5.1 billion in 2024, then rose by 11.83% to $5.7 billion in 2025, then gained by 0.66% to $5.7 billion in 2026.
• Per Business Quant, the three latest VRTX Long-Term Investments figures stand at $5.7 billion (Q1 2026), $5.7 billion (Q4 2025), and $5.7 billion (Q3 2025).